California Peptide Research提供客戶的多肽合成定制服務(wù),包括肥胖抑制素, β淀粉樣腎臟髓質(zhì)素肽, 內(nèi)皮素, 內(nèi)皮素拮抗劑。
a-Secretase Substrate | 1.0 mg | 165 |
Acetyl-Arg-(Glu-Edans)-Val-His-His-Gln-Lys-Leu-Val-Phe-(Dabcyl-Lys)-Arg-OH | ||
a-Secretase Substrate | 5.0 mg | 655 |
Acetyl-Arg-(Glu-Edans)-Val-His-His-Gln-Lys-Leu-Val-Phe-(Dabcyl-Lys)-Arg-OH | ||
Abarelix | 1.0 mg | 130 |
Acetyl-(D-Naphtyl-Ala )-(p-Chloro-D-Phenylalanine)-(Pyridyl-Ala)-Ser-(NMe-Tyr)-D-Asp-Leu-(Iso-Lys)-Pro-D-Ala-NH2 | ||
Abarelix | 5.0 mg | 530 |
Acetyl-(D-Naphtyl-Ala )-(p-Chloro-D-Phenylalanine)-(Pyridyl-Ala)-Ser-(NMe-Tyr)-D-Asp-Leu-(Iso-Lys)-Pro-D-Ala-NH2 | ||
Ac-Arg-Ala-Arg-AMC | 5.0 mg | 125 |
Acetyl-Arg-Ala-Arg-AMC | ||
Acetyl Beta Amyloid (25-35) | 1.0 mg | 55 |
Acetyl-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-OH | ||
Acetyl Beta Amyloid (25-35) | 5.0 mg | 205 |
Acetyl-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-OH | ||
Acetyl-Ala-Arg-AMC | 10.0 mg | 110 |
Acetyl-Ala-Arg-AMC | ||
Acetyl-Arg-Ala-Val-AMC | 5.0 mg | 110 |
Acetyl-Arg-Ala-Val-AMC | ||
Acetyl-Arg-Glu-Lys-Arg-AFC | 5.0 mg | 120 |
Acetyl-Arg-Glu-Lys-Arg-AFC | ||
Acetyl-Arg-Gly-Phe-Phe-Pro-AFC | 5.0 mg | 140 |
Acetyl-Arg-Gly-Phe-Phe-Pro-AFC | ||
Acetyl-Arg-Gly-Phe-Phe-Pro-AMC | 5.0 mg | 110 |
Acetyl-Arg-Gly-Phe-Phe-Pro-AMC | ||
Acetyl-Arg-Ser-Leu-Lys-AMC | 5.0 mg | 110 |
Acetyl-Arg-Ser-Leu-Lys-AMC | ||
Acetyl-Glu-Val-Asn-Leu-AFC | 5.0 mg | 120 |
Acetyl-Glu-Val-Asn-Leu-AFC | ||
Acetyl-Glu-Val-Asn-Leu-AMC | 5.0 mg | 110 |
Acetyl-Glu-Val-Asn-Leu-AMC | ||
Acetyl-Glu-Val-Asn-Leu-pNA | 5.0 mg | 90 |
Acetyl-Glu-Val-Asn-Leu-pNA | ||
Acetyl-Leu-Gln-Thr-Asp-AFC | 5.0 mg | 120 |
Acetyl-Leu-Gln-Thr-Asp-AFC | ||
Acetyl-Leu-Leu-Arg-AMC | 5.0 mg | 110 |
Acetyl-Leu-Leu-Arg-AMC | ||
Acetyl-Leu-Leu-Leu-AFC | 5.0 mg | 120 |
Acetyl-Leu-Leu-Leu-AFC | ||
Acetyl-Lys-Gln-Lys-Leu-Arg-4-methoxy-2-naphtylamide | 5.0 mg | 120 |
Acetyl-Lys-Gln-Lys-Leu-Arg-4-methoxy-2-naphtylamide | ||
Acetyl-Lys-Pro-Arg-AFC | 5.0 mg | 120 |
Acetyl-Lys-Pro-Arg-AFC | ||
Acetyl-Lys-Pro-Arg-AMC | 5.0 mg | 110 |
Acetyl-Lys-Pro-Arg-AMC | ||
Acetyl-Neurotensin (8-13) | 1.0 mg | 35 |
Acetyl-Arg-Arg-Pro-Tyr-Ile-Leu-OH | ||
Acetyl-Neurotensin (8-13) | 5.0 mg | 105 |
Acetyl-Arg-Arg-Pro-Tyr-Ile-Leu-OH | ||
Acetyl-Phe-Ile-Pro-Ala-Ser-Leu-Arg-AFC | 5.0 mg | 150 |
Acetyl-Phe-Ile-Pro-Ala-Ser-Leu-Arg-AFC | ||
Acetyl-Phe-Ser-Arg-pNA | 5.0 mg | 90 |
Acetyl-Phe-Ser-Arg-pNA | ||
Acetyl-Pro-Glu-Asp-Glu-AFC | 5.0 mg | 120 |
Acetyl-Pro-Glu-Asp-Glu-AFC | ||
Acetyl-Pro-Leu-Ser-Ser-Ile-Phe-Ser-Arg-Ile-Gly-Asp-Pro-Arg-Lys-Gly-Asp-Glu-Val-Asp-AFC | 5.0 mg | 185 |
Acetyl-Pro-Leu-Ser-Ser-Ile-Phe-Ser-Arg-Ile-Gly-Asp-Pro-Arg-Lys-Gly-Asp-Glu-Val-Asp-AFC | ||
Acetyl-Ser-Asp-Lys-Pro | 5.0 mg | 35 |
Acetyl-Ser-Asp-Lys-Pro | ||
Acetyl-Val-Glu-Ile-Ala-AFC | 5.0 mg | 120 |
Acetyl-Val-Glu-Ile-Ala-AFC | ||
ACTH (1-17) human | 1.0 mg | 80 |
Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-OH | ||
ACTH (1-17) human | 5.0 mg | 315 |
Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-OH | ||
ACTH (1-24), human | 1.0 mg | 80 |
Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro-OH | ||
ACTH (1-24), human | 5.0 mg | 315 |
Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro-OH | ||
ACTH (1-39), rat | 1.0 mg | 205 |
Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro-Asn-Val-Ala-Glu-Asn-Glu-Ser-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH | ||
ACTH (7-38), human / Corticotropin Inhibiting Peptide (7-38) | 1.0 mg | 120 |
Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Glu-Ser-Ala-Glu-Ala-Phe-Pro-Leu-Glu-OH | ||
ACTH (7-38), human / Corticotropin Inhibiting Peptide (7-38) | 5.0 mg | 485 |
Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Glu-Ser-Ala-Glu-Ala-Phe-Pro-Leu-Glu-OH | ||
ADAM substrate | 1.0 mg | 230 |
(Glu-EDANS)-Lys-Pro-Ala-Lys-Phe-Phe-Arg-Leu-(Dabcyl-Lys)-NH2 | ||
ADAM substrate | 5.0 mg | 895 |
(Glu-EDANS)-Lys-Pro-Ala-Lys-Phe-Phe-Arg-Leu-(Dabcyl-Lys)-NH2 | ||
Adamantaneacetyl-[DArg0,Hyp3,Thi5,8,DPhe7] Bradykinin | 1.0 mg | 60 |
Adamataneacetyl-D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-D-Phe-Thi-Arg-OH | ||
Adamantaneacetyl-[DArg0,Hyp3,Thi5,8,DPhe7] Bradykinin | 5.0 mg | 210 |
Adamataneacetyl-D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-D-Phe-Thi-Arg-OH | ||
Adrenal Secretogranin, bovine | 5.0 mg | 155 |
Phe-Pro-Lys-Pro-Ala-Gly-Ser-Gln-Asp-Lys-Pro-Leu-His-Asn-OH | ||
Adrenomedullin (1-50), rat | 0.5 mg | 310 |
Tyr-Arg-Gln-Ser-Met-Asn-Gln-Gly-Ser-Arg-Ser-Thr-Gly-Cys-Arg-Phe-Gly-Thr-Cys-Thr-Met-Gln-Lys-Leu-Ala-His-Gln-Ile-Tyr-Gln-Phe-Thr-Asp-Lys-Asp-Lys-Asp-Gly-Met-Ala-Pro-Arg-Asn-Lys-Ile-Ser-Pro-Gln-Gly-Tyr-NH2 | ||
Adrenomedullin (1-50), rat | 1.0 mg | 500 |
Tyr-Arg-Gln-Ser-Met-Asn-Gln-Gly-Ser-Arg-Ser-Thr-Gly-Cys-Arg-Phe-Gly-Thr-Cys-Thr-Met-Gln-Lys-Leu-Ala-His-Gln-Ile-Tyr-Gln-Phe-Thr-Asp-Lys-Asp-Lys-Asp-Gly-Met-Ala-Pro-Arg-Asn-Lys-Ile-Ser-Pro-Gln-Gly-Tyr-NH2 | ||
Adrenomedullin (1-52), human | 0.5 mg | 310 |
Tyr-Arg-Gln-Ser-Met-Asn-Asn-Phe-Gln-Gly-Leu-Arg-Ser-Phe-Gly-Cys-Arg-Phe-Gly-Thr-Cys-Thr-Val-Gln-Lys-Leu-Ala-His-Gln-Ile-Tyr-Gln-Phe-Thr-Asp-Lys-Asp-Lys-Asp-Asn-Val-Ala-Pro-Arg-Ser-Lys-Ile-Ser-Pro-Gln-Gly-Tyr-NH2 | ||
Adrenomedullin (1-52), human | 1.0 mg | 500 |
Tyr-Arg-Gln-Ser-Met-Asn-Asn-Phe-Gln-Gly-Leu-Arg-Ser-Phe-Gly-Cys-Arg-Phe-Gly-Thr-Cys-Thr-Val-Gln-Lys-Leu-Ala-His-Gln-Ile-Tyr-Gln-Phe-Thr-Asp-Lys-Asp-Lys-Asp-Asn-Val-Ala-Pro-Arg-Ser-Lys-Ile-Ser-Pro-Gln-Gly-Tyr-NH2 | ||
Adrenomedullin (11-50), rat | 0.5 mg | 230 |
Ser-Thr-Gly-Cys-Arg-Phe-Gly-Thr-Cys-Thr-Met-Gln-Lys-Leu-Ala-His-Gln-Ile-Tyr-Gln-Phe-Thr-Asp-Lys-Asp-Lys-Asp-Gly-Met-Ala-Pro-Arg-Asn-Lys-Ile-Ser-Pro-Gln-Gly-Tyr-NH2 | ||
Adrenomedullin (11-50), rat | 1.0 mg | 395 |
Ser-Thr-Gly-Cys-Arg-Phe-Gly-Thr-Cys-Thr-Met-Gln-Lys-Leu-Ala-His-Gln-Ile-Tyr-Gln-Phe-Thr-Asp-Lys-Asp-Lys-Asp-Gly-Met-Ala-Pro-Arg-Asn-Lys-Ile-Ser-Pro-Gln-Gly-Tyr-NH2 | ||
Adrenomedullin (22-52), human | 0.5 mg | 160 |
Thr-Val-Gln-Lys-Leu-Ala-His-Gln-Ile-Tyr-Gln-Phe-Thr-Asp-Lys-Asp-Lys-Asp-Asn-Val-Ala-Pro-Arg-Ser-Lys-Ile-Ser-Pro-Gln-Gly-Tyr-NH2 | ||
Adrenomedullin (22-52), human | 1.0 mg | 240 |
Thr-Val-Gln-Lys-Leu-Ala-His-Gln-Ile-Tyr-Gln-Phe-Thr-Asp-Lys-Asp-Lys-Asp-Asn-Val-Ala-Pro-Arg-Ser-Lys-Ile-Ser-Pro-Gln-Gly-Tyr-NH2 | ||
Agatoxin IVa ( SS Cys 4,20 / Cys 12,25 / Cys 19,36 / Cys 27 | 0.5 mg | 835 |
Lys-Lys-Lys-Cys-Ile-Ala-Lys-Asp-Tyr-Gly-Arg-Cys-Lys-Trp-Gly-Gly-Thr-Pro-Cys-Cys-Arg-Gly-Arg-Gly-Cys-Ile-Cys-Ser-Ile-Met-Gly-Thr-Asn-Cys-Glu-Cys-Lys-Pro-Arg-Leu-Ile-Met-Glu-Gly-Leu-Gly-Leu-Ala-OH | ||
Agatoxin IVa ( SS Cys 4,20 / Cys 12,25 / Cys 19,36 / Cys 27 | 1.0 mg | 1525 |
Lys-Lys-Lys-Cys-Ile-Ala-Lys-Asp-Tyr-Gly-Arg-Cys-Lys-Trp-Gly-Gly-Thr-Pro-Cys-Cys-Arg-Gly-Arg-Gly-Cys-Ile-Cys-Ser-Ile-Met-Gly-Thr-Asn-Cys-Glu-Cys-Lys-Pro-Arg-Leu-Ile-Met-Glu-Gly-Leu-Gly-Leu-Ala-OH | ||
Akt Substrate | 5.0 mg | 105 |
Arg-Pro-Arg-Ala-Ala-Thr-Phe-NH2 | ||
All D Beta Amyloid (1-40), human | 0.5 mg | 395 |
D-Asp-D-Ala-D-Glu-D-Phe-D-Arg-D-His-D-Asp-D-Ser-Gly-D-Tyr-D-Glu-D-Val-D-His-D-His-D-Gln-D-Lys-D-Leu-D-Val-D-Phe-D-Phe-D-Ala-D-Glu-D-Asp-D-Val-Gly-D-Ser-D-Asn-D-Lys-Gly-D-Ala-D-Ile-D-Ile-Gly-D-Leu-D-Met-D-Val-Gly-Gly-D-Val-D-Val-OH | ||
All D Beta Amyloid (1-40), human | 1.0 mg | 685 |
D-Asp-D-Ala-D-Glu-D-Phe-D-Arg-D-His-D-Asp-D-Ser-Gly-D-Tyr-D-Glu-D-Val-D-His-D-His-D-Gln-D-Lys-D-Leu-D-Val-D-Phe-D-Phe-D-Ala-D-Glu-D-Asp-D-Val-Gly-D-Ser-D-Asn-D-Lys-Gly-D-Ala-D-Ile-D-Ile-Gly-D-Leu-D-Met-D-Val-Gly-Gly-D-Val-D-Val-OH | ||
Allatostatin B2, cockroach | 1.0 mg | 105 |
Ala-Tyr-Ser-Tyr-Val-Ser-Glu-Tyr-Lys-Arg-Leu-Pro-Val-Tyr-Asn-Phe-Gly-Leu-NH2 | ||
Alpha Atrial Natriuretic Polypeptide (1-28), human / ANP (1- | 0.5 mg | 125 |
Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Met-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-OH | ||
Alpha Atrial Natriuretic Polypeptide (1-28), human / ANP (1- | 1.0 mg | 205 |
Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Met-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-OH | ||
Alpha MSH Ac-Nle4 c[Asp5, D-Phe7, Lys10] (4-10) amide | 1.0 mg | 60 |
Acetyl-050-Asp-His-011-Arg-Trp-Lys-NH2 | ||
Alpha MSH Ac-Nle4 c[Asp5, D-Phe7, Lys10] (4-10) amide | 5.0 mg | 215 |
Acetyl-050-Asp-His-011-Arg-Trp-Lys-NH2 | ||
Alpha MSH [D-Phe7] | 1.0 mg | 60 |
Acetyl-Ser-Tyr-Ser-Met-Glu-His-011-Arg-Trp-Gly-Lys-Pro-Val-NH2 | ||
Alpha MSH [D-Phe7] | 5.0 mg | 215 |
Acetyl-Ser-Tyr-Ser-Met-Glu-His-011-Arg-Trp-Gly-Lys-Pro-Val-NH2 | ||
Alpha MSH [Nle4,D-Phe7] | 1.0 mg | 60 |
Acetyl-Ser-Tyr-Ser-050-Glu-His-011-Arg-Trp-Gly-Lys-Pro-Val-NH2 | ||
Alpha MSH [Nle4,D-Phe7] | 5.0 mg | 215 |
Acetyl-Ser-Tyr-Ser-050-Glu-His-011-Arg-Trp-Gly-Lys-Pro-Val-NH2 | ||
Alpha MSH, Ac-NLe4c[Asp5,DNal7,Lys10](4-10) amide | 1.0 mg | 60 |
Acetyl-050-Asp-His-038-Arg-Trp-Lys-NH2 | ||
Alpha MSH, Ac-NLe4c[Asp5,DNal7,Lys10](4-10) amide | 5.0 mg | 215 |
Acetyl-050-Asp-His-038-Arg-Trp-Lys-NH2 | ||
Amylin (1-37) NH2, human / Islet Amyloid Polypeptide (IAPP), | 1.0 mg | 295 |
Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-His-Ser-Ser-Asn-Asn-Phe-Gly-Ala-Ile-Leu-Ser-Ser-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-NH2 | ||
Amylin (1-37) NH2, human / Islet Amyloid Polypeptide (IAPP), | 5.0 mg | 1315 |
Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-His-Ser-Ser-Asn-Asn-Phe-Gly-Ala-Ile-Leu-Ser-Ser-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-NH2 | ||
Amylin (1-37) NH2, human / Islet Amyloid Polypeptide (IAPP), | 10.0 mg | 2520 |
Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-His-Ser-Ser-Asn-Asn-Phe-Gly-Ala-Ile-Leu-Ser-Ser-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-NH2 | ||
Amylin, rat | 0.5 mg | 135 |
Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-Arg-Ser-Ser-Asn-Asn-Leu-Gly-Pro-Val-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-NH2 | ||
Amylin, rat | 1.0 mg | 230 |
Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-Arg-Ser-Ser-Asn-Asn-Leu-Gly-Pro-Val-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-NH2 | ||
Amyloid Blocker | 5.0 mg | 85 |
Acetyl-Gln-Lys-Leu-Val-Phe-Phe-NH2 | ||
Amyloid fragment (Pro18,Asp21) (17-21) | 5.0 mg | 105 |
Leu-Pro-Phe-Phe-Asp-OH | ||
Amyloid precursor | 1.0 mg | 135 |
Mca-Ser-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Arg-(DNP-Lys)-Arg-Arg-NH2 | ||
Amyloid precursor | 5.0 mg | 525 |
Mca-Ser-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Arg-(DNP-Lys)-Arg-Arg-NH2 | ||
Angiotensin Fragment ( 1-7 ) Acetate | 5.0 mg | 55 |
Asp-Arg-Val-Tyr-Ile-His-Pro-OH | ||
Angiotensin I [Asn1,Val5,Asn9], salmon | 1.0 mg | 30 |
Asn-Arg-Val-Tyr-Val-His-Pro-Phe-Asn-Leu-OH | ||
Angiotensin I [Asn1,Val5,Asn9], salmon | 5.0 mg | 105 |
Asn-Arg-Val-Tyr-Val-His-Pro-Phe-Asn-Leu-OH | ||
Angiotensin I [Val5,Asn9], bullfrog | 1.0 mg | 30 |
Asp-Arg-Val-Tyr-Val-His-Pro-Phe-Asn-Leu-OH | ||
Angiotensin I [Val5,Asn9], bullfrog | 5.0 mg | 105 |
Asp-Arg-Val-Tyr-Val-His-Pro-Phe-Asn-Leu-OH | ||
Angiotensin I/II (1-5) | 1.0 mg | 45 |
Asp-Arg-Val-Tyr-Ile-OH | ||
Angiotensin II [Sar1,Ile8] | 1.0 mg | 30 |
034-Arg-Val-Tyr-Ile-His-Pro-Ile-OH | ||
Angiotensin II [Sar1,Ile8] | 5.0 mg | 100 |
034-Arg-Val-Tyr-Ile-His-Pro-Ile-OH | ||
Angiotensin II, human | 5.0 mg | 35 |
Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-OH | ||
Angiotensin II-[Sar1] | 5.0 mg | 80 |
034-Arg-Val-Tyr-Ile-His-Pro-Phe-OH | ||
Angiotensin III, human) / Angiotensin II-[Des Asp1] | 10.0 mg | 55 |
Arg-Val-Tyr-Ile-His-Pro-Phe-OH | ||
Angiotensinogen (1-14) Renin Substrate (porcine) | 1.0 mg | 40 |
Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-Leu-Val-Tyr-Ser-OH | ||
Angiotensinogen (1-14) Renin Substrate (porcine) | 10.0 mg | 185 |
Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-Leu-Val-Tyr-Ser-OH | ||
ANP (123-150), rat / ANP (6-33), rat / ANP (1-28), rat | 0.5 mg | 125 |
Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-OH | ||
ANP (123-150), rat / ANP (6-33), rat / ANP (1-28), rat | 1.0 mg | 205 |
Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-OH | ||
ANP (126-150), rat / Auriculin B, ANP (4-28), rat | 0.5 mg | 125 |
Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-OH | ||
ANP (126-150), rat / Auriculin B, ANP (4-28), rat | 1.0 mg | 205 |
Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-OH | ||
ANP (4-24), frog | 1.0 mg | 165 |
Cys-Phe-Gly-Ser-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Met-Gly-Cys-Gly-Arg-Arg-Phe-OH | ||
ANP Des[18-22] (4-23) amide, rat | 1.0 mg | 125 |
Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Cys-NH2 | ||
Antennapedia Peptide | 1.0 mg | 80 |
Arg - Gln - Ile - Lys - Ile - Trp - Phe - Gln - Asn - Arg - Arg - Met - Lys - Trp - Lys - Lys | ||
Apamin, bee venom (SS1-11)(SS3-15) | 0.5 mg | 105 |
Cys-Asn-Cys-Lys-Ala-Pro-Glu-Thr-Ala-Leu-Cys-Ala-Arg-Arg-Cys-Gln-Gln-His-NH2 | ||
Apamin, bee venom (SS1-11)(SS3-15) | 1.0 mg | 160 |
Cys-Asn-Cys-Lys-Ala-Pro-Glu-Thr-Ala-Leu-Cys-Ala-Arg-Arg-Cys-Gln-Gln-His-NH2 | ||
APP (354-371) | 1.0 mg | 135 |
Lys-Ala-Val-Ile-Gln-His-Phe-Gln-Glu-Lys-Val-Glu-Ser-Leu-Glu-Gln-Glu-Ala-OH | ||
APP (354-371) | 5.0 mg | 525 |
Lys-Ala-Val-Ile-Gln-His-Phe-Gln-Glu-Lys-Val-Glu-Ser-Leu-Glu-Gln-Glu-Ala-OH | ||
APP Beta Secretase Inhibitor | 1.0 mg | 160 |
Lys-Thr-Glu-Glu-Ile-Ser-Glu-Val-Asn-200-Val-Ala-Glu-Phe-OH | ||
APP gamma secretase inhibitor | 5.0 mg | 60 |
3-5 difluorophenacetyl-Ala-217-t-Butylester | ||
APP gamma secretase inhibitor | 5.0 mg | 60 |
3-5 difluorophenacetyl-Ala-(S-Phenylglycine)-Methylester | ||
Arg-Glu(EDANS)-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-(e-Dabcyl-Lysine)-Arg-OH | 1.0 mg | 135 |
Arg-Glu(EDANS)-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-(e-Dabcyl-Lysine)-Arg-OH | ||
Arg-Leu-Lys-Gly-Gly-AFC | 5.0 mg | 140 |
Arg-Leu-Lys-Gly-Gly-AFC | ||
Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln-OH | 5.0 mg | 120 |
Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln-OH | ||
Asp-Glu-Val-Asp-AFC | 5.0 mg | 120 |
Asp-Glu-Val-Asp-AFC | ||
Atriopeptine III, rat;ANP (127-150), rat | 0.5 mg | 115 |
Ser-Ser-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-OH | ||
Atriopeptine III, rat;ANP (127-150), rat | 1.0 mg | 185 |
Ser-Ser-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-OH | ||
Autocamptide-2 Related Inhibitoy Peptide | 5.0 mg | 105 |
Lys-Lys-Ala-Leu-Arg-Arg-Gln-Glu-Ala-Val-Asp-Ala-Leu-OH | ||
Autocamptide-2 Related Inhibitoy Peptide | 5.0 mg | 105 |
Myristoyl-Lys-Lys-Ala-Leu-Arg-Arg-Gln-Glu-Ala-Val-Asp-Ala-Leu-OH | ||
BAM (6-22) Quote : 6920 | 0.5 mg | 125 |
Arg-Arg-Val-Gly-Arg-Pro-Glu-Trp-Trp-Met-Asp-Tyr-Gln-Lys-Arg-Tyr-Gly-OH | ||
BAM (6-22) Quote : 6920 | 1.0 mg | 185 |
Arg-Arg-Val-Gly-Arg-Pro-Glu-Trp-Trp-Met-Asp-Tyr-Gln-Lys-Arg-Tyr-Gly-OH | ||
BAM 3200 Bovine Adrenal Medulla Peptide E | 0.5 mg | 175 |
Tyr-Gly-Gly-Phe-Met-Arg-Arg-Val-Gly-Arg-Pro-Glu-Trp-Trp-Met-Asp-Tyr-Gln-Lys-Arg-Tyr-Gly-Gly-Phe-Leu-OH | ||
BAM 3200 Bovine Adrenal Medulla Peptide E | 1.0 mg | 290 |
Tyr-Gly-Gly-Phe-Met-Arg-Arg-Val-Gly-Arg-Pro-Glu-Trp-Trp-Met-Asp-Tyr-Gln-Lys-Arg-Tyr-Gly-Gly-Phe-Leu-OH | ||
Beta Amyloid (1-16) [Gln11], human | 0.5 mg | 60 |
Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Gln-Val-His-His-Gln-Lys-OH | ||
Beta Amyloid (1-16) [Gln11], human | 1.0 mg | 85 |
Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Gln-Val-His-His-Gln-Lys-OH | ||
Beta Amyloid (1-16) [Gln11], human | 5.0 mg | 320 |
Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Gln-Val-His-His-Gln-Lys-OH | ||
Beta Amyloid (1-16), rat | 1.0 mg | 90 |
Asp-Ala-Glu-Phe-Gly-His-Asp-Ser-Gly-Phe-Glu-Val-Arg-His-Gln-Lys-OH | ||
Beta Amyloid (1-16), rat | 5.0 mg | 340 |
Asp-Ala-Glu-Phe-Gly-His-Asp-Ser-Gly-Phe-Glu-Val-Arg-His-Gln-Lys-OH | ||
Beta Amyloid (1-28), [Gln11], human | 0.5 mg | 95 |
Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Gln-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-OH |